Skip to main content
36°
Sunny
Site search
Search
Menu
Search
Subscribe
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
News
Local News
State News
Sports
Local Sports
Pro Sports
Lifestyle
Local Entertainment
Multimedia
Community Choice
Features
Special Sections
Local Events
Weather
Classifieds
Place Ad
Legal Notices
Place Call Legal
Search Call Legals
Place Times Legal
Search Times Legals
Public Notices
Obituaries
E-Edition
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
RAPT Therapeutics, Inc. - Common Stock
(NQ:
RAPT
)
0.7905
-0.0106 (-1.32%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Apr 17, 2025
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about RAPT Therapeutics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
Next >
Recap: RAPT Therapeutics Q3 Earnings
November 13, 2023
Via
Benzinga
RAPT Therapeutics Reports Third Quarter 2023 Financial Results
November 13, 2023
Company maintains strong cash position of $184.8 million
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC
November 03, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in November
November 01, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Analyst Ratings for RAPT Therapeutics
September 14, 2023
Via
Benzinga
The Latest Analyst Ratings for RAPT Therapeutics
August 09, 2023
Via
Benzinga
RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
October 18, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
7 ‘Strong Buy’ Biotech Stocks to Rejuvenate Your Portfolio
September 27, 2023
Dive into these seven strong buy biotech stocks, handpicked by Wall Street, to inject vigor into your investment game.
Via
InvestorPlace
Benzinga's Top Ratings Upgrades, Downgrades For September 14, 2023
September 14, 2023
Via
Benzinga
Analyst Ratings for RAPT Therapeutics
June 05, 2023
Via
Benzinga
Analyst Expectations for RAPT Therapeutics's Future
May 12, 2023
Via
Benzinga
Recap: RAPT Therapeutics Q1 Earnings
May 11, 2023
Via
Benzinga
The Latest Analyst Ratings for RAPT Therapeutics
March 15, 2023
Via
Benzinga
RAPT Therapeutics to Participate in Several Upcoming Investor Conferences in September
August 30, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Reports Second Quarter 2023 Financial Results
August 11, 2023
Company maintains strong cash position of $205 million
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For August 9, 2023
August 09, 2023
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For June 15, 2023
June 15, 2023
Via
Benzinga
RAPT Therapeutics to Participate in the Goldman Sachs Global Healthcare Conference
June 07, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics to Present Biomarker Data Corroborating Demonstrated Clinical Activity and Mechanism of Action of FLX475 in Advanced Cancers
May 25, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Reports First Quarter 2023 Financial Results
May 11, 2023
Company maintains strong cash position of $231.6 million
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Announces the Appointment of Michael Listgarten as General Counsel
May 03, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
RAPT Therapeutics Announces FLX475 Poster Presentation at the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
April 26, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
Why Satsuma Pharmaceuticals Shares Are Trading Higher By 94%? Here Are Other Stocks Moving In Monday's Mid-Day Session
April 17, 2023
Gainers ContraFect Corporation (NASDAQ: CFRX) shares surged 213% to $2.82.
Via
Benzinga
Why Marpai Shares Are Trading Lower By 26%; Here Are 20 Stocks Moving Premarket
April 17, 2023
Gainers CNS Pharmaceuticals, Inc. (NASDAQ: CNSP) jumped 153% to $5.96 in pre-market trading after jumping 243% on Friday.
Via
Benzinga
Prometheus Biosciences, XPeng And Other Big Stocks Moving Higher In Monday's Pre-Market Session
April 17, 2023
U.S. stock futures traded mixed this morning. Here are some big stocks recording gains in today’s pre-market trading session. Prometheus Biosciences, Inc. (NASDAQ: RXDX) shares jumped 70.1% to $193.93...
Via
Benzinga
RAPT Therapeutics Announces Initiation of Phase 2a Trial of RPT193 in Patients with Moderate-to-Severe Asthma
March 29, 2023
From
RAPT Therapeutics, Inc.
Via
GlobeNewswire
The 7 Best Biotech ETFs to Buy for Exposure to the Healthcare Sector
March 15, 2023
To play a permanently relevant industry with the broadest canvas possible, consider acquiring the best biotech ETFs to buy.
Via
InvestorPlace
S&P 500 Rises 1%; Crude Oil Down Over 4%
March 14, 2023
U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite gaining over 1.5% on Tuesday. The Dow traded up 0.40% to 31,945.39 while the NASDAQ rose 1.58% to 11,365.53. The S&P 500,...
Via
Benzinga
Dow Extends Rebound, Surges 456 Points
March 14, 2023
Rallying bank stocks are fueling Wall Street's midday gains, as investors continue to unpack this morning's consumer price index (CPI) data.
Via
Talk Markets
12 Health Care Stocks Moving In Tuesday's Intraday Session
March 14, 2023
Via
Benzinga
< Previous
1
2
3
4
5
6
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.